{"id":92066,"date":"2016-12-14T11:58:31","date_gmt":"2016-12-14T11:58:31","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=92066"},"modified":"2016-12-14T11:58:31","modified_gmt":"2016-12-14T11:58:31","slug":"global-injectable-drug-delivery-market-is-anticipated-to-reach-usd-9311-billion-by-2024","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-injectable-drug-delivery-market-is-anticipated-to-reach-usd-9311-billion-by-2024_92066.html","title":{"rendered":"Global Injectable Drug Delivery Market is Anticipated to Reach USD 931.1 Billion by 2024"},"content":{"rendered":"<div style=\" width:250px; padding:8px 10px 10px 10px; float:right;\"><a href=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2016\/12\/1481698787.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"image\" src=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2016\/12\/1481698787.png\" alt=\"\" width=\"200\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\" style=\" font-weight:bold; font-style:italic;\">\n<div>&#8220;Orbis Research&#8221;<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">OrbisResearch.com has published new research report on &#8220;Global Injectable Drug Delivery Market Analysis, By Device Type (Self-injection Devices, Conventional Devices), By Formulation (Conventional Drug Delivery, Novel Drug Delivery), By Therapeutic Use (Autoimmune Disorders, Hormonal Disorders, Oncology), By End-user Application (Hospitals, Homecare Settings, Research Institutes, Clinical Laboratories), By Region And Segment Forecasts From 2013 to 2024&#8221; to its database.<\/div>\n<p style=\"text-align: justify;\">The global injectable drug delivery market is expected to reach USD 931.1 billion by 2024, according to a new report by Grand View Research, Inc. The increase in number of chronic diseases like diabetes and cancer has fueled the need for injectable drug delivery. Unlike other traditional forms of drug delivery, injectables allow maximum bioavailability of the pharmaceutical drug as it bypasses the first pass metabolism. With substantial growth in technological advancements, the devices being manufactured and marketed are built so as to cater to the specific needs of the patients.<\/p>\n<p style=\"text-align: justify;\"><strong>Browse the report: <\/strong><a rel=\"nofollow\" href=\"http:\/\/www.orbisresearch.com\/reports\/index\/injectable-drug-delivery-market-analysis-by-device-type-formulation-formulation-end-user-application-user-application-and-segment-forecasts-from-2013-to-2024\" target=\"_blank\">http:\/\/www.orbisresearch.com\/reports\/index\/injectable-drug-delivery-market-analysis-by-device-type-formulation-formulation-end-user-application-user-application-and-segment-forecasts-from-2013-to-2024 <\/a><\/p>\n<p>With the advent of self-injection devices, injectable drugs can be self administered without the need of medical assistance. A large number of technology-oriented developments have taken place in the biologics market, which further increases the applicability of these injectable devices in the challenging disease areas. Self-injection devices have allowed patients suffering from diabetes to manage insulin levels with auto-injectors, pen-injectors, and needle-free injectors; thus, the homecare segment has been a large grosser in the end-user application.<\/p>\n<p>The major restraints in this market are injuries and infections caused by needles, ambiguities related to regulatory reimbursements, sterility of the injectable drugs, and the preference of other drug delivery systems that possess less toxicity and are easy to administer. Despite these restraints, the market potential for injectable drug delivery products is tremendous with majority of the key players opting to injectables over other forms of delivery. The injectable drug delivery industry, based on product type is segmented into two sub-types namely self-injection devices and conventional injection devices. Further, on the basis of therapeutic use, the injectable drug delivery industry is segmented into autoimmune disorders, hormonal disorders, oncology, and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample of the report: <\/strong><a rel=\"nofollow\" href=\"http:\/\/www.orbisresearch.com\/contacts\/request-sample\/112779\" target=\"_blank\">http:\/\/www.orbisresearch.com\/contacts\/request-sample\/112779<\/a><\/p>\n<p>The injectable drug delivery industry by end-user application is categorized into hospitals, homecare settings, and others including research establishments, diagnostics, and clinical laboratories.<\/p>\n<p><strong>Further key findings from the study suggest:<\/strong><\/p>\n<p>North America is expected to lead the market for injectable drug delivery devices with the largest number of patients suffering from chronic diseases like diabetes and cancer along with autoimmune disorders. The reason why countries in North America are leading is due to the technological innovations and advanced research in the area that enable them to excel at designing new and improved drug delivery products.<\/p>\n<p style=\"text-align: justify;\"><strong>Buy the report@<\/strong><a rel=\"nofollow\" href=\"http:\/\/www.orbisresearch.com\/contact\/purchase\/112779\" target=\"_blank\">http:\/\/www.orbisresearch.com\/contact\/purchase\/112779<\/a><\/p>\n<p>The Asia Pacific market is set to lead exceptionally well owing to the partnerships with other well established global players. This region has also witnessed enormous investments in research and development; thus, accelerating the growth of the injectables market in this region.<\/p>\n<p>The homecare settings has been the most profit garnering segment with a large cohort of patients suffering from chronic diseases and hence the resultant high utility of these devices at a primary level for better control and management of the disease.<\/p>\n<p>Some key market players include Pfizer, Inc., Schott AG, Becton, Dickinson and Company, Baxter International, Inc., and ELI Lilly &amp; Co.<\/p>\n<p style=\"text-align: justify;\"><strong>Major points From table Of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Chapter One: Methodology and Scope<\/p>\n<p style=\"text-align: justify;\">Chapter Two: Executive Summary<\/p>\n<p style=\"text-align: justify;\">Chapter Three: Injectable Drug DeliveryIndustry Outlook<\/p>\n<p style=\"text-align: justify;\">Chapter Four: Injectable Drug Delivery Product Type Outlook<\/p>\n<p style=\"text-align: justify;\">Chapter Five: Injectable Drug Delivery Therapeutic Use Outlook<\/p>\n<p style=\"text-align: justify;\">Chapter Six: Injectable Drug Delivery End-User Application Outlook<\/p>\n<p style=\"text-align: justify;\">Chapter Seven: Injectable Drug Delivery Regional Outlook<\/p>\n<p style=\"text-align: justify;\">Chapter Eight: Competitive Landscape<\/p>\n<p style=\"text-align: justify;\"><strong>About Us:<\/strong><\/p>\n<p style=\"text-align: justify;\">Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> Orbis Research<br \/><strong>Contact Person:<\/strong> Hector Costello<br \/><strong>Email:<\/strong> sales@orbisresearch.com<br \/><strong>Phone:<\/strong> +1 (214) 884-6817<br \/><strong>Address:<\/strong>4144N Central Expressway, Suite 600  <br \/><strong>City:<\/strong> Dallas<br \/><strong>State:<\/strong> Texas<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.orbisresearch.com\/reports\/index\/injectable-drug-delivery-market-analysis-by-device-type-formulation-formulation-end-user-application-user-application-and-segment-forecasts-from-2013-to-2024\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.orbisresearch.com\/reports\/index\/injectable-drug-delivery-market-analysis-by-device-type-formulation-formulation-end-user-application-user-application-and-segment-forecasts-from-2013-to-2024<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.orbisresearch.com\/reports\/index\/injectable-drug-delivery-market-analysis-by-device-type-formulation-formulation-end-user-application-user-application-and-segment-forecasts-from-2013-to-2024\" style=\"width:605px; height:400px;\"><\/object><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=global-injectable-drug-delivery-market-is-anticipated-to-reach-usd-9311-billion-by-2024\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Orbis Research&#8221; OrbisResearch.com has published new research report on &#8220;Global Injectable Drug Delivery Market Analysis, By Device Type (Self-injection Devices, Conventional Devices), By Formulation (Conventional Drug Delivery, Novel Drug Delivery), By Therapeutic Use (Autoimmune Disorders, Hormonal Disorders, Oncology), By End-user &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/global-injectable-drug-delivery-market-is-anticipated-to-reach-usd-9311-billion-by-2024_92066.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-92066","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/92066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=92066"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/92066\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=92066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=92066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=92066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}